|Articles|February 28, 2021

New COVID-19 Variant Identified in New York

The variant, B.1.526, was first found in samples dating back to November.

In recent days a new COVID-19 variant first identified in New York had been reported. The variant, B.1.526, was found in samples dating back to last November.

The discovery was reported on Medrxiv.

Investigators are reporting the variant has been seen throughout New York City, has been found in older people, and has seen more frequently hospitalized patients.

“We observed a steady increase in the detection rate from late December to mid-February, with an alarming rise to 12.3% in the past two weeks,” the investigators wrote. “Whole genome sequencing further demonstrated that most of our E484K isolates (n=49/65) fell within a single lineage: NextStrain clade 20C or Pangolin lineage B.1.526.”

According to LiveScience, there are 2 mutations that could be problematic and have some in the medical community concerned. “One branch has a mutation called E484K, which has also been seen in other coronavirus variants, including those identified in South Africa and Brazil. This mutation may reduce the ability of certain antibodies to neutralize, or inactivate, the virus, and may help the coronavirus partially evade COVID-19 vaccines,” the website reported.

It now appears it's a race between the emerging variants and getting people vaccinated more quickly.

“Again, that’s the reason why keep doing the public health measures and get as many people vaccinated as you possibly can,” Anthony Fauci, MD, a medical advisor to the Biden Administration, who was interviewed on CNN late last week. “Everything you throw at us about a mutant is going to be countered by getting people vaccinated.”

With the FDA's Emergency Use Authorization (EUA) of the Janssen COVID-19 vaccine yesterday, this marks the third vaccine to achieve an EUA in the United States, and will help with the needed supplies for mass vaccination.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.